Bremelanotide is FDA-approved for women: what Vyleesi actually treats
The short version: branded bremelanotide is approved for one specific condition in premenopausal women.
TL;DR
- Branded bremelanotide (Vyleesi) is FDA-approved for premenopausal women with HSDD.
- Compounded PT-141 is the same molecule but is not FDA-approved.
- The label covers a specific population, dose schedule, and indication — not “any low desire.”
What it is
Bremelanotide is a synthetic peptide that activates melanocortin receptors (in plain English: a family of receptors in the brain that influence appetite, skin pigmentation, and sexual desire). Branded as Vyleesi by Palatin Technologies and approved by the FDA in 2019, it is the only peptide in this class FDA-approved for HSDD (in plain English: hypoactive sexual desire disorder — persistent low sexual desire that causes personal distress) in premenopausal women (FDA Vyleesi label, 2019).
How it works
Think of melanocortin receptors as a row of doorbells in the brain that influence different behaviors. Bremelanotide presses one specific doorbell — the MC4R doorbell — that nudges sexual desire pathways. It does not work on blood flow the way Viagra does. The label’s published mechanism narrative describes activation of central melanocortin receptors involved in sexual response, with effects independent of vascular changes (FDA Vyleesi label, 2019).
Who asks about it
People ask this when they have read about PT-141 from a peptide clinic and want to know whether the molecule is “real” — meaning FDA-approved for any indication. The answer is yes for the branded product, in one specific population.
What the research says
In the registration trials supporting Vyleesi’s approval, premenopausal women with HSDD reported improvements in desire scores and a reduction in distress scores compared with placebo (Kingsberg et al., Obstet Gynecol, 2019). The most common side effect was nausea, reported in roughly 4 in 10 participants — usually within the first hour after injection. Other side effects included flushing, headache, and transient blood pressure increases. The label limits use to no more than once per 24 hours and no more than 8 doses per month.
What to know before considering it
Vyleesi is for premenopausal women with acquired, generalized HSDD — meaning the loss of desire is new and not tied to a single partner or context. It is not approved for postmenopausal women, men, or low desire caused by medical conditions, medications, or relationship factors. A clinician evaluation is required, including a blood pressure check.
The Halftime POV
Vyleesi is a useful reference point. It tells us that “PT-141” is not vaporware — the FDA has approved this molecule for one specific use. It also tells us that compounded versions occupy a different regulatory category.
Related reading:
- PT-141 (bremelanotide): how melanocortin signaling affects desire
- How PT-141 signals desire through melanocortin receptors
- PT-141 for women: the brain-based path to desire
FAQ
Q: Is bremelanotide FDA-approved for women? A: Yes. Branded bremelanotide (Vyleesi) is FDA-approved for premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD). Compounded PT-141 is not FDA-approved.
Q: What is HSDD? A: HSDD stands for hypoactive sexual desire disorder — persistent low sexual desire that causes personal distress and is not better explained by another medical condition, medication, or relationship issue.
Q: How is Vyleesi taken? A: Vyleesi is a single-dose subcutaneous injection used at least 45 minutes before anticipated sexual activity, no more than once every 24 hours and no more than 8 doses per month.
Disclaimer
This article is educational and is not medical advice. Compounded medications are not FDA-approved. Clinical outcomes depend on individual factors and require physician evaluation. Results vary. Halftime Health is launching soon — join the waitlist to get updates.
Get updates
Halftime Health is launching soon. We’ll share what we learn along the way — the research, the regulations, the real-world trade-offs. Join the waitlist and we’ll email you when we’re live.
